<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E7910513-EA16-41B2-A0C0-7F49C936A4BF"><gtr:id>E7910513-EA16-41B2-A0C0-7F49C936A4BF</gtr:id><gtr:name>University of Wales</gtr:name><gtr:address><gtr:line1>University Registry</gtr:line1><gtr:line2>King Edward VII Ave</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF10 3NS</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A56659BA-683E-45AE-AB1C-DA0690F1DA7D"><gtr:id>A56659BA-683E-45AE-AB1C-DA0690F1DA7D</gtr:id><gtr:firstName>Awen</gtr:firstName><gtr:surname>Gallimore</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G117%2F488"><gtr:id>9AC27F12-495F-410A-BADD-360D6DD20AA9</gtr:id><gtr:title>Characterisation of the phenotypic and functional characteristics of CD25+ regulatory T cells in vivo.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G117/488</gtr:grantReference><gtr:abstractText>Our immune systems recognise infectious agents responding in a variety of ways resulting in eradication of the particular pathogen involved. Whilst ridding the body of infectious agents, the immune system must not destroy healthy tissue ( a process termed autoimmunity). In the majority of cases the immune system is able to discriminate between infected and healthy tissue, however, 3 - 5 % of the general population suffer from autoimmune diseases e.g. multiple sclerosis and type I diabetes, indicating that under certain circumstances control mechanisms within the immune system do break down. On the other hand, cancer cells are normally not attacked by the immune system since these cells resemble healthy and not infected tissue. Thus in this situation it would be beneficial to be able to manipulate the immune system in a way which would override normal control mechanisms thereby allowing destruction of the tumour cells. The aim of this research is to gain an understanding of pathways, which control how the immune system perceives what is healthy and what is harmful. Such an understanding is an essential pre-requisite for the design of strategies aimed at treating individuals suffering from either autoimmune disease or cancer.</gtr:abstractText><gtr:technicalSummary>The overall aim of this project is to understand how the immune system is able to discriminate between healthy tissue and infected tissue. The importance of this aim stems from the fact that when the ability to discriminate breaks down, attack of healthy tissue by the immune system can result in the development of autoimmune disease such as diabetes and arthritis. Conversely, cancer cells are normally not attacked by the immune system since these cells resemble healthy tissue and not infected tissue. Understanding ways in which the immune system discriminates between healthy and infected tissue is central to the design of therapeutic strategies aimed at treating both autoimmune disease and cancer. An accumulating body of evidence suggests that the function of a population of lymphocytes, named CD25+ regulatory cells, is to prevent the immune system from targeting healthy tissue. It has been shown, in animal models, that these cells inhibit the development of immune responses against cancer. Similarly, it has been shown that these cells can inhibit development of autoimmune disease. Many features of these cells are not well understood. This laboratory, based at the University of Wales College of Medicine, has established an experimental model whereby the impact of CD25+ regulatory T cells on both autoimmune disease and tumour immunity can be studied within the same experimental setting. This model will be used to determine the biological parameters, which govern the activity of CD25+ regulatory cells. The success of this project depends upon both national and international collaborations. Thus, collaborators include Dr Philippe Gasque at the University of Wales College of Medicine, Dr Simon Jones at the University of Cardiff, Dr Persephone Borrow at the Jenner Institute for Vaccine Research, Dr Annette Oxenius at the University of Zurich, Professor Hans-Joerg Schild at the University of Tuebingen and Dr Fiona Powrie at the University of Oxford. The clinical benefits of manipulating CD25+ regulatory cells are potentially very significant. Enhancing the activity of these cells may prevent autoimmunity whilst suppressing their activity may promote immunity to tumours. This projects aims to develop an understanding of how CD25+ regulatory cells work in order that their full potential as targets for immunotherapy can be realised.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>935917</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection and Immunity</gtr:department><gtr:description>Evaluating the Role of Regulatory T cells in Patients with Cancer</gtr:description><gtr:id>76324AAF-028F-4D76-9530-0B2D565175FC</gtr:id><gtr:impact>17205133
PhD studentship from Cancer Research Wales
Wellcome Trust University Award</gtr:impact><gtr:outcomeId>F3C44DAB60D-2</gtr:outcomeId><gtr:partnerContribution>Enabled our findings using animals models to be rapidly tested in patients with cancerExpertise in human immunology</gtr:partnerContribution><gtr:piContribution>Use of assays to perform phenotypic and functional characterisation of regulatory T cells in patients with cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection and Immunity</gtr:department><gtr:description>Role of CD62L in homing of anti-viral and anti-tumour T cells</gtr:description><gtr:id>8AD1F7C3-F7D1-4D4C-BEDB-145874D9182E</gtr:id><gtr:impact>Publication in the Journal of Immunology</gtr:impact><gtr:outcomeId>iMtvqgmTWvE-1</gtr:outcomeId><gtr:partnerContribution>Provision of mice and expertise to enable the study of T cell homing</gtr:partnerContribution><gtr:piContribution>Provision of experimental model to study T cell homing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Evaluating the Role of Regulatory T cells in Patients with Cancer</gtr:description><gtr:id>19D304BC-DEE2-43A4-9210-3EEF2EDB0B86</gtr:id><gtr:impact>17205133
PhD studentship from Cancer Research Wales
Wellcome Trust University Award</gtr:impact><gtr:outcomeId>F3C44DAB60D-1</gtr:outcomeId><gtr:partnerContribution>Enabled our findings using animals models to be rapidly tested in patients with cancerExpertise in human immunology</gtr:partnerContribution><gtr:piContribution>Use of assays to perform phenotypic and functional characterisation of regulatory T cells in patients with cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection and Immunity</gtr:department><gtr:description>Evaluating the Role of CD59 in Modulating CD4+ T cells</gtr:description><gtr:id>4E99D325-2B05-4D7A-8400-34F5FC6B7155</gtr:id><gtr:impact>Two papers in Journal of Immunology
One paper in European Journal of Immunology
Review in Trends in Immunology</gtr:impact><gtr:outcomeId>cLRHG4HoB59-1</gtr:outcomeId><gtr:partnerContribution>Provision of mice, reagents and expertise</gtr:partnerContribution><gtr:piContribution>Generated mouse models of virus infection to test role of CD59 in modulating T cell activity
Provision of cohort of cancer patients and assays to test role of CD59 in modulating activity of human T cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Documentary for BBC World</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1DC17478-338A-400A-B581-A69DE4FCCCEA</gtr:id><gtr:impact>A film sponsored by the AICR was produced and televised on BBC World.

I have no information regarding its audience.</gtr:impact><gtr:outcomeId>6E3F581E517</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>GW4</gtr:fundingOrg><gtr:id>E5CF88F1-5C64-46F2-91E2-3F6F8201DAB4</gtr:id><gtr:outcomeId>58b58567594583.14710927</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>Cancer Research Wales</gtr:fundingOrg><gtr:id>4828CF4F-9C5E-4576-AD75-2D318AB5E3F2</gtr:id><gtr:outcomeId>58b584779c7465.54412984</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>829539</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust University Award (Identification of mechanisms underpinning regulatory T cell involvement in disease)</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3C94A14C-4010-4B93-BF3F-1C9C044AE8EF</gtr:id><gtr:outcomeId>134D8F99D630</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>168228</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (CD59 as a modulator of T cell activity in vivo)</gtr:description><gtr:end>2008-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>60E1C174-9E54-4B67-A72E-2C1E5801EB5F</gtr:id><gtr:outcomeId>0BDA0831D940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247075</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (The Role of Interleukin-6 in Generation and Maintenance of Influenza-Specific CD4+ T Cell Memory)</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B842BDB4-D7A5-4EA6-9BD1-EA88CD34829D</gtr:id><gtr:outcomeId>B1F4C63D0250</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>7FB2C7FE-7316-4CD3-BA02-A21E9B971281</gtr:id><gtr:outcomeId>58b5850d4c8f05.48337853</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>498000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C6CC864D-72FE-4E5D-880C-4FF3AC2BE4B1</gtr:id><gtr:outcomeId>2017825E6D00</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The intervention was a pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX&amp;reg;) vaccination in patients with inoperable metastatic colorectal cancer.
In this randomised, open-label, phase 2 clinical trial, TaCTiCC (TroVax&amp;reg; and Cyclophosphamide Treatment in Colorectal Cancer), we recruited patients with inoperable, metastatic CRC, with prior stable or responding disease following 12 weeks standard chemotherapy. Patients were centrally randomised to receive either no treatment (watch &amp;amp; wait unless clinically indicated; Group 1), metronomic oral 50mg B.D. CPM on treatment weeks 1 &amp;amp; 3 (Group 2), intramuscular injections of 1x109 TCID50 TroVax&amp;reg; on treatment weeks 4, 6, 8, 10, 12 and 16 (Group 3), or a combination of the two treatments (Group 4). The primary endpoint was the magnitude of anti-5T4 immune responses generated at treatment week 7, as determined by the presence of 5T4-specific T cell responses by IFN-? ELISPOT and 5T4 antibodies by ELISA. Secondary endpoints included analysing the kinetics of anti-5T4 responses, progression-free survival (PFS) and overall survival (OS). This trial is registered with EudraCT (2010-024380-41) and the ISRCTN registry</gtr:description><gtr:id>2A62A419-7A14-4CF3-B50E-31D068673246</gtr:id><gtr:impact>Prior depletion of Tregs by CPM does not boost immune responses generated to TroVax&amp;reg; vaccination, however, both CPM and TroVax&amp;reg; independently induced beneficial anti-tumour immune responses resulting in prolonged survival of end-stage CRC patients without toxicity. These data warrant further investigation of the two treatments in separate, larger clinical trials.Funding applications are underway.</gtr:impact><gtr:outcomeId>58b58bd1a0e277.81173956</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>CLINICAL TRIAL - TACTICC</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>82D9B5CA-E6AA-4B30-8E83-BB9769B7A959</gtr:id><gtr:title>Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/246d843e37510a3a54f0e2764657203b"><gtr:id>246d843e37510a3a54f0e2764657203b</gtr:id><gtr:otherNames>Hindley JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>gvjxxzvgg6e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19F8C3A-0FD7-40F9-A0FA-0C67E838605C</gtr:id><gtr:title>CD62L (L-selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27c01ff007a6bb9440f557dfd2e7065"><gtr:id>d27c01ff007a6bb9440f557dfd2e7065</gtr:id><gtr:otherNames>Richards H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>89E82DEBCA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64469919-EF23-4889-86EE-EEA1B4D33443</gtr:id><gtr:title>Regulatory T cells and tumour immunity - observations in mice and men.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc4f5378766d97fb82ac4c56d99bd173"><gtr:id>dc4f5378766d97fb82ac4c56d99bd173</gtr:id><gtr:otherNames>Gallimore A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>03B0217B13E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1324D2BD-9005-4B91-808C-138DB2C3CB70</gtr:id><gtr:title>CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6e620f85cf08dfc7d4e9d2da9a94ac0"><gtr:id>f6e620f85cf08dfc7d4e9d2da9a94ac0</gtr:id><gtr:otherNames>Longhi MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>C989D49A796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>638275DB-08A4-4B5C-8842-19940D306AE6</gtr:id><gtr:title>Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab8cd03f216c1b37bd6aafc5bac659d5"><gtr:id>ab8cd03f216c1b37bd6aafc5bac659d5</gtr:id><gtr:otherNames>Lauder SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_15212_22_23857287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3BEBBEF-6066-4D6F-8E04-2A975A07EF42</gtr:id><gtr:title>Holding T cells in check--a new role for complement regulators?</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6e620f85cf08dfc7d4e9d2da9a94ac0"><gtr:id>f6e620f85cf08dfc7d4e9d2da9a94ac0</gtr:id><gtr:otherNames>Longhi MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>99A8A780266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EC02AF3-653B-4BC1-BDB5-68320A77C57F</gtr:id><gtr:title>Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b68080e88149e335f2dfb51dded0fd3f"><gtr:id>b68080e88149e335f2dfb51dded0fd3f</gtr:id><gtr:otherNames>Cuff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>86AA2E37505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D915EC7-0352-49C3-9C49-54F772E35AFE</gtr:id><gtr:title>CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c50fdf20c74fb7c3df0baa3dd44568e"><gtr:id>7c50fdf20c74fb7c3df0baa3dd44568e</gtr:id><gtr:otherNames>Clarke SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>EEEAD5531D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB626F9E-2823-4F3E-93B4-A905FF5A1F84</gtr:id><gtr:title>Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6e620f85cf08dfc7d4e9d2da9a94ac0"><gtr:id>f6e620f85cf08dfc7d4e9d2da9a94ac0</gtr:id><gtr:otherNames>Longhi MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>2B735963BEF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>310755FB-BA76-4FCC-A707-CE6FBAD9FEA8</gtr:id><gtr:title>Potent T cell agonism mediated by a very rapid TCR/pMHC interaction.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9633af825b05487fae52582801ead272"><gtr:id>9633af825b05487fae52582801ead272</gtr:id><gtr:otherNames>Boulter JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>D8598645051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76443DAB-2A79-4098-8D29-794676C5FEC7</gtr:id><gtr:title>The impact of regulatory T cells on carcinogen-induced sarcogenesis.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e91fffe206cb1e737057bda6fec65cc"><gtr:id>8e91fffe206cb1e737057bda6fec65cc</gtr:id><gtr:otherNames>Betts G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>4BD60909FA7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E26AAB60-19D9-4FA2-A0AF-692123F9E1BD</gtr:id><gtr:title>Positive and negative influences of regulatory T cells on tumour immunity.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0f77d489eb6fb438049a61a1b0d6338"><gtr:id>f0f77d489eb6fb438049a61a1b0d6338</gtr:id><gtr:otherNames>Gallimore AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>1299CB8ACAE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F70F883A-EBC8-4195-9383-C9111AF12BC4</gtr:id><gtr:title>Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab8cd03f216c1b37bd6aafc5bac659d5"><gtr:id>ab8cd03f216c1b37bd6aafc5bac659d5</gtr:id><gtr:otherNames>Lauder SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_15212_22_21310755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6639A4C6-FA83-4AD0-AF4B-CE2E8BB1169E</gtr:id><gtr:title>Novel role of regulatory T cells in limiting early neutrophil responses in skin.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27c01ff007a6bb9440f557dfd2e7065"><gtr:id>d27c01ff007a6bb9440f557dfd2e7065</gtr:id><gtr:otherNames>Richards H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>BGxPfkWP4y7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D89820-3A4D-4442-B2BE-E357AD575C0C</gtr:id><gtr:title>CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33a6cfd4af384fd38321f8b03bfdb5c2"><gtr:id>33a6cfd4af384fd38321f8b03bfdb5c2</gtr:id><gtr:otherNames>Sivasankar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>BBD470252B7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AEB0765-3CEE-4ABA-B46C-B4BE211952BA</gtr:id><gtr:title>Regulating the immune response to tumours.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e93b2ed7c5ea49000fa0311556b85b"><gtr:id>52e93b2ed7c5ea49000fa0311556b85b</gtr:id><gtr:otherNames>Betts GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>F7EAC9FD484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3A4F86A-8D9F-4386-99AD-64BAFB96CF02</gtr:id><gtr:title>Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4d299adf7084288162fca806b41cff6"><gtr:id>b4d299adf7084288162fca806b41cff6</gtr:id><gtr:otherNames>Gallagher KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>2C546EF6FAA</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G117/488</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>